MetaVia shares surge 126.72% after-hours on positive Phase 1 trial results for DA-1726 obesity drug.

MetaVia Inc. (NASDAQ:MTVA) surged 126.72% in after-hours trading following the announcement of a 1-for-11 reverse stock split, effective December 4, 2025, to comply with Nasdaq’s minimum bid price requirements. The move reduces outstanding shares from ~25.4 million to ~2.3 million, aligning with shareholder-approved measures taken at the June 30, 2025, annual meeting. The reverse split aims to stabilize the stock price, enhance market perception, and ensure continued Nasdaq listing. Fractional shares will be rounded down, with shareholders compensated in cash for any value lost. This strategic action directly addresses recent Nasdaq delisting concerns and is the most immediate catalyst for the stock’s dramatic after-hours rally.